EMG
GYRE icon

Ellington Management Group’s Gyre Therapeutics GYRE Stock Holding History

Ellington Management Group’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,520
Closed -$129K – 632
2019
Q4 		$129K Buy
+2,520
New +$106K 0.03% 480
2018
Q2 		– Sell
-2,240
Closed -$433K – 629
2018
Q1 		$433K Buy
+2,240
New +$418K 0.03% 456

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Ellington Management Group's GYRE Position: Q1 2020 in Review

Ellington Management Group sold out of Gyre Therapeutics (GYRE) in Q1 2020, closing a stake of 2,520 shares — an estimated $129K sold.

Ellington Management Group first reported a position in GYRE in Q1 2018 and held it in 2 quarters. The position peaked at $433K in Q1 2018. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2020.

  • Ellington Management Group reported no remaining Gyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Ellington Management Group sold 2,520 Gyre Therapeutics shares in Q1 2020, an estimated $129K.
  • Ellington Management Group first reported a position in Gyre Therapeutics in Q1 2018 and held it in 2 quarters.
  • Ellington Management Group's Gyre Therapeutics position peaked at $433K in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.